D000972Chemicals & DrugsD27.505.954.248.17910190.9892Antineoplastic Agents, Phytogenicprns:emailEncryptedemail addressFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson30309721Monk BJ, Kauderer JT, Moxley KM, Bonebrake AJ, Dewdney SB, Secord AA, Ueland FR, Johnston CM, Aghajanian CGynecologic oncologyA phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2018 12; 151(3):422-427.Gynecol Oncol2018-10-08T00:00:002018A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.Rush University, College of Health SciencesPhilipBonomiPhilip Bonomi349183Bonomi, PhilipProfessorEunsilHahmEunsil Hahm349302Hahm, EunsilAssistant ProfessorHealth Systems ManagementChien-ChingLiS7oUFZMv3dXRdlPgs7kiUtrvKXfc7tg=Chien-Ching Li349399Li, Chien-ChingAssistant ProfessorSummerDewdneySummer Dewdney349599Dewdney, SummerAssistant Professor6Assistant Professor4Professor0.8845540.034716210research area of0.6843010.040555621subject area for29702555Chang CP, Chan YY, Li CF, Chien LH, Lee ST, Wu TFNutrientsDeciphering the Molecular Mechanism Underlying the Inhibitory Efficacy of Taiwanese Local Pomegranate Peels against Urinary Bladder Urothelial Carcinoma. Nutrients. 2018 Apr 27; 10(5).Nutrients2018-04-27T00:00:002018Deciphering the Molecular Mechanism Underlying the Inhibitory Efficacy of Taiwanese Local Pomegranate Peels against Urinary Bladder Urothelial Carcinoma.18160686Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NEThe New England journal of medicinePaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27; 357(26):2666-76.N Engl J Med2007-12-27T00:00:002007Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.26616224Burton ER, Brady M, Homesley HD, Rose PG, Nakamura T, Kesterson JP, Rotmensch J, Tate Thigpen J, Van Le LGynecologic oncologyA phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study. Gynecol Oncol. 2016 Jan; 140(1):48-52.Gynecol Oncol2015-11-23T00:00:002015A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study.Rush University, Rush Medical CollegeInternal Medicine, Division of Hematology/Oncology/Cell TherapyObstetrics and GynecologyEunsilHahmEunsil Hahm349823Hahm, EunsilAssistant Professor19089452Bleibel WK, Duan S, Huang RS, Kistner EO, Shukla SJ, Wu X, Badner JA, Dolan MEHuman geneticsIdentification of genomic regions contributing to etoposide-induced cytotoxicity. Hum Genet. 2009 Mar; 125(2):173-80.Hum Genet2008-12-17T00:00:002008Identification of genomic regions contributing to etoposide-induced cytotoxicity.true1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant ProfessorInternal Medicine, Division of Nephrologytrue1Assistant ProfessorAssistant Professor